Home Stock

Stock Research: Aktis Oncology

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Aktis Oncology

NSQ:AKTS US00973N1028
73
  • Value
    80
  • Growth
    79
  • Safety
    Safety
    23
  • Combined
    78
  • Sentiment
    51
  • 360° View
    360° View
    73
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

ATech (Parent) Resolution Corp., formerly Akoustis Technologies, Inc., is not engaged in any business operating activity and has no assets. In the last fiscal year, the company had a market cap of $0 million, profits of $-1 million, revenue of $27 million, and 117 employees.

more

ANALYSIS: With an Obermatt 360° View of 73 (better than 73% compared with alternatives), overall professional sentiment and financial characteristics for the stock Aktis Oncology are above average. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Aktis Oncology. The consolidated Value Rank has an attractive rank of 80, which means that the share price of Aktis Oncology is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 80% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 79, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 51. But the company’s financing is risky with a Safety rank of 23. This means 77% of comparable companies have a safer financing structure than Aktis Oncology. ...read more

more
Strongest Rank Dividend Yield
Weakest Rank Revenue Growth
Country USA
Industry Biotechnology
Size X-Small
Website aktisoncology.com
Index
NASDAQ
Aktis Oncology stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 87 61 41
Growth
79 23 57 63
Safety
Safety
23 1 46 70
Sentiment
51 11 29 67
360° View
360° View
73 12 46 85
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
65 85 86 84
Opinions Change
95 50 50 50
Pro Holdings
n/a 5 25 67
Market Pulse
50 4 12 20
Sentiment
51 11 29 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
80 87 61 41
Growth
79 23 57 63
Safety Safety
23 1 46 70
Combined
78 23 61 65
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
34 100 65 25
Price vs. Earnings (P/E)
62 24 24 24
Price vs. Book (P/B)
72 96 92 64
Dividend Yield
1 1 1 1
Value
80 87 61 41
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
96 55 100 98
Profit Growth
50 92 72 30
Capital Growth
89 4 65 87
Stock Returns
15 3 3 3
Growth
79 23 57 63
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
63 1 42 100
Refinancing
43 4 79 63
Liquidity
5 7 7 15
Safety Safety
23 1 46 70

Similar Stocks

Discover high‑ranked alternatives to Aktis Oncology and broaden your portfolio horizons.

Zimmer

NYQ:ZBH
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Resideo Technologies

NYQ:REZI
Country: USA
Industry: Building Products
Size: Large
Full Stock Analysis

Peabody Energy

NYQ:BTU
Country: USA
Industry: Coal & Consumable Fuels
Size: Large
Full Stock Analysis

Innoviva

NSQ:INVA
Country: USA
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews